Izba is owned by Novartis.
Izba contains Travoprost.
Izba has a total of 4 drug patents out of which 0 drug patents have expired.
Izba was authorised for market use on 15 May, 2014.
Izba is available in solution/drops;ophthalmic dosage forms.
The generics of Izba are possible to be released after 10 October, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(5 years from now) | |
US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(6 years from now) | |
US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
8
United States
4
European Union
3
Denmark
3
Spain
2
Hong Kong
2
Germany
2
China
2
Japan
1
South Africa
1
Mexico
1
Australia
1
Russia
1
Slovenia
1
Hungary
1
Uruguay
1
Argentina
1
Brazil
1
Portugal
1
Korea, Republic of
1
Poland
1
Chile
1
Taiwan, Province of China
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic